Abstract
Novel anti-vasculature strategies that are emerging for the treatment of cancer and for the inhibition of angiogenesis may be a promising new tool for the adjuvant therapy of malignant tumours. Over the last fifteen years, several reports have been published concerning the relationship between tumour progression and angiogenesis in experimental models of neuroblastoma in vitro and in vivo. Moreover, a high vascular index in neuroblastoma correlates with poor prognosis, suggesting dependence of aggressive tumour growth on active angiogenesis. Here, we present an overview of the most recent advances in anti-vasculature therapy of neuroblastoma, and describe some preclinical results as well as future perspectives.
Keywords: Liposomes, ligand-mediated targeting, peptides, phage display, angiogenesis, anti-tumour drugs, neuroblastoma
Current Drug Targets
Title: Recent Advances in Targeted Anti-Vasculature Therapy: The Neuroblastoma Model
Volume: 10 Issue: 10
Author(s): F. Pastorino, D. Di Paolo, M. Loi, P. Becherini, I. Caffa, A. Zorzoli, D. Marimpietri, R. Carosio, P. Perri, P. G. Montaldo, C. Brignole, G. Pagnan, D. Ribatti, T. M. Allen and M. Ponzoni
Affiliation:
Keywords: Liposomes, ligand-mediated targeting, peptides, phage display, angiogenesis, anti-tumour drugs, neuroblastoma
Abstract: Novel anti-vasculature strategies that are emerging for the treatment of cancer and for the inhibition of angiogenesis may be a promising new tool for the adjuvant therapy of malignant tumours. Over the last fifteen years, several reports have been published concerning the relationship between tumour progression and angiogenesis in experimental models of neuroblastoma in vitro and in vivo. Moreover, a high vascular index in neuroblastoma correlates with poor prognosis, suggesting dependence of aggressive tumour growth on active angiogenesis. Here, we present an overview of the most recent advances in anti-vasculature therapy of neuroblastoma, and describe some preclinical results as well as future perspectives.
Export Options
About this article
Cite this article as:
Pastorino F., Di Paolo D., Loi M., Becherini P., Caffa I., Zorzoli A., Marimpietri D., Carosio R., Perri P., Montaldo G. P., Brignole C., Pagnan G., Ribatti D., Allen M. T. and Ponzoni M., Recent Advances in Targeted Anti-Vasculature Therapy: The Neuroblastoma Model, Current Drug Targets 2009; 10 (10) . https://dx.doi.org/10.2174/138945009789577954
DOI https://dx.doi.org/10.2174/138945009789577954 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bone Morphogenetic Protein-Smad Pathway as Drug Targets for Osteoporosis and Cancer Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Cerium Oxide Nanoparticles Trigger Neuronal Survival in a Human Alzheimer Disease Model By Modulating BDNF Pathway
Current Nanoscience Development of a Novel and Robust Pharmacological Model of Okadaic Acid-induced Alzheimer’s Disease in Zebrafish
CNS & Neurological Disorders - Drug Targets Feud or Friend? The Role of the miR-17-92 Cluster in Tumorigenesis
Current Genomics Preparation and Quality Control of <sup>111</sup>In-Plerixafor for Chemokine Receptor CXCR4
Recent Patents and Topics on Imaging (Discontinued) Strain Specificity and Drug Resistance in Anti-Prion Therapy
Current Topics in Medicinal Chemistry Determining the Oligomer Number of Native GPCR Using Florescence Correlation Spectroscopy and Drug-Induced Inactivation-Reactivation
Current Pharmaceutical Biotechnology Immunological Mechanisms of Neuropsychiatric Lupus
Current Immunology Reviews (Discontinued) Cellular Toxicity of Mesoporous Silica Nanoparticle in SHSY5Y and BMMNCs Cell
Pharmaceutical Nanotechnology Hepatocyte Growth Factor and Insulin-like Growth Factor-1 based Cellular Therapies for Oxidative Stress Injury
Current Stem Cell Research & Therapy Targeting the Resistance of Pancreatic Cancer Cells to Nutrient Deprivation: Anti-Austerity Compounds
Current Drug Delivery NAD<sup>+</sup>/NADH Metabolism and NAD<sup>+</sup>-Dependent Enzymes in Cell Death and Ischemic Brain Injury: Current Advances and Therapeutic Implications
Current Medicinal Chemistry Prolyl Oligopeptidase, Inositol Phosphate Signalling and Lithium Sensitivity
CNS & Neurological Disorders - Drug Targets Induction of Synthetic Lethality by Natural Compounds Targeting Cancer Signaling
Current Pharmaceutical Design Chinese Herbs and Herbal Extracts for Neuroprotection of Dopaminergic Neurons and Potential Therapeutic Treatment of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Nanofibre Based Smart Pharmaceutical Scaffolds for Wound Repair and Regenerations
Current Pharmaceutical Design Adenosine and ATP Receptors in the Brain
Current Topics in Medicinal Chemistry BRI2 Interacts with BACE1 and Regulates Its Cellular Levels by Promoting its Degradation and Reducing Its mRNA Levels
Current Alzheimer Research Cerebral Amyloidoses: Molecular Pathways and Therapeutic Challenges
Current Medicinal Chemistry Biosafety of Onco-Retroviral Vectors
Current Gene Therapy